Kezar Life Sciences, Inc. Update: The Company is Being Acquired

If you have followed Kezar Life Sciences’ difficult journey, there is finally a major update. After clinical trial setbacks, a 41% workforce reduction in late 2024, and a pivot away from its lead drug, the company is being bought out. Here is what this means for you.

1. What happened?

On March 30, 2026, Kezar Life Sciences agreed to be acquired by Aurinia Pharmaceuticals. Instead of operating independently—which cost the company $128 million in losses during 2025—Kezar will become a subsidiary of Aurinia.

2. What does this mean for shareholders?

If you own Kezar stock (KZR), you are being cashed out. The deal has two parts:

• Cash Payment: You will receive $6.955 per share in cash. This values the company at approximately $140 million.
• The "Bonus" Ticket (CVR): You will also receive one "Contingent Value Right" (CVR) for every share you own. This gives you the right to extra cash if specific goals are met within 24 months.
  • The Goals: Payouts happen if the company successfully sells the rights to its zetomipzomib drug or hits regulatory milestones for its other programs.
  • Note: These CVRs cannot be traded on an exchange. They will expire worthless if the goals are not met by March 2028. The company didn't provide much detail on the specific probability of these milestones being met, so it is best to view these as a long-shot lottery ticket.

3. Why is this happening?

Kezar hit a wall in October 2024. It stopped its main lupus drug trial after reports of fatal side effects. This failure destroyed the company's primary value. With only $85 million in cash left by the end of 2025, the company risked running out of money entirely. By selling to Aurinia, Kezar gives shareholders a clear exit while handing off expensive research costs to a more stable company.

4. What is the timeline?

• The Offer: Aurinia will start its offer to buy all KZR shares within 10 business days of the March 30 announcement.
• The Closing: The deal should finish in the second quarter of 2026, assuming regulators approve it.
• The "No-Shop" Clause: Kezar cannot look for other buyers. If Kezar breaks the deal to accept a better offer, it must pay a $1.2 million fee.

5. What should you do?

• If you are a trader: The stock price will likely hover near the $6.955 offer price. Because the CVRs are tied to assets that have already faced significant clinical hurdles, most of the value here is in the guaranteed cash payment.
• If you are an employee: The company is winding down. Stock options priced below $6.955 will be cashed out. Options priced above $6.955 will be cancelled.
• Watch for updates: Keep an eye on your brokerage account for a "Letter of Transmittal." You must formally tender your shares through your broker to get paid.

6. The Bottom Line

This acquisition ends Kezar’s time as an independent company. The $6.955 cash payment offers a clear exit, but the CVRs are speculative and should not be counted on as a reliable source of future income. If you are holding KZR, your primary focus should be on the upcoming tender offer process to ensure you receive your cash payout.

---

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.